Tag: JSC 2026

  • EU-HTA 2026: Can Pharma Fix PICO Challenges Before Phase III?

    EU-HTA 2026: Can Pharma Fix PICO Challenges Before Phase III?

    —

    by

    in

    EU-HTA’s 2026 Scientific Consultation Window: Can Pharma Fix Tomorrow’s PICO Problems Before Phase III? Europe’s pharmaceutical evidence landscape is changing. Under the EU Health Technology Assessment (HTA) Regulation, generating strong clinical evidence is no longer sufficient on its own. Pharmaceutical companies must also consider whether their clinical development programmes will address the comparative evidence needs…